Dynavax Technologies Corporation  

(Public, NASDAQ:DVAX)   Watch this stock  
Find more results for Carson Gray´┐Ż
28.41
+0.55 (1.97%)
Sep 4 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 27.12 - 28.70
52 week 13.20 - 31.10
Open 27.55
Vol / Avg. 196,269.00/579,735.00
Mkt cap 1.09B
P/E     -
Div/yield     -
EPS -3.75
Shares 38.40M
Beta 2.85
Inst. own 75%
Nov 3, 2015
Q3 2015 Dynavax Technologies Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 10, 2015
Dynavax Technologies Corp at BioCentury NewsMakers in the Biotech Industry Conference - 8:30AM EDT - Add to calendar
Sep 9, 2015
Dynavax Technologies Corp at FBR Healthcare Conference Add to calendar
Aug 7, 2015
Q2 2015 Dynavax Technologies Corp Earnings Release
Jun 11, 2015
Dynavax Technologies Corp at William Blair Annual Growth Stock Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -1522.00% -822.35%
Operating margin -1498.97% -827.69%
EBITD margin - -814.97%
Return on average assets -85.38% -52.91%
Return on average equity -126.50% -63.27%
Employees 197 -
CDP Score - -

Address

2929 7th St Ste 100
BERKELEY, CA 94710-2753
United States - Map
+1-510-8485100 (Phone)
+1-510-8481327 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The Company’s pipeline of product candidates includes HEPLISAV-B, an investigational adult hepatitis B vaccine, is in Phase III clinical trials; SD-101, a cancer immunotherapy candidate, is in Phase I/II clinical trials; AZD1419, a candidate drug for asthma, is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases, is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.

Officers and directors

Arnold L. Oronsky Ph.D. Independent Chairman of the Board
Age: 75
Bio & Compensation  - Reuters
Eddie Gray Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Michael S. Ostrach Principal Financial Officer, Vice President, General Counsel, Chief Business Officer
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Robert L. Coffman Ph.D. Senior Vice President, Chief Scientific Officer
Age: 68
Bio & Compensation  - Reuters
David F. Novack Senior Vice President - Operations and Quality
Age: 53
Bio & Compensation  - Reuters
David L Johnson Chief Accounting Officer, Vice President
Age: 57
Bio & Compensation  - Reuters
Robert Janssen M.D. Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs
Age: 61
Bio & Compensation  - Reuters
Laura A. Brege Director
Age: 57
Bio & Compensation  - Reuters
Natale S. Ricciardi Director
Age: 66
Bio & Compensation  - Reuters
Francis R. Cano Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters